Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001737287-23-000041
Filing Date
2023-04-24
Accepted
2023-04-24 16:06:28
Documents
21

Document Format Files

Seq Description Document Type Size
1 DEF 14A allo-20230422.htm   iXBRL DEF 14A 857456
6 allo-20230422_g1.jpg GRAPHIC 19512
7 allo-20230422_g2.jpg GRAPHIC 180690
8 allo-20230422_g3.jpg GRAPHIC 55258
9 allo-20230422_g4.jpg GRAPHIC 36833
10 allo-20230422_g5.jpg GRAPHIC 26773
11 allo-20230422_g6.jpg GRAPHIC 227875
12 allo-20230422_g7.jpg GRAPHIC 316301
  Complete submission text file 0001737287-23-000041.txt   3515366

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20230422.xsd EX-101.SCH 4020
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20230422_def.xml EX-101.DEF 5151
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20230422_lab.xml EX-101.LAB 7985
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20230422_pre.xml EX-101.PRE 4786
15 EXTRACTED XBRL INSTANCE DOCUMENT allo-20230422_htm.xml XML 143985
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38693 | Film No.: 23840093
SIC: 2836 Biological Products, (No Diagnostic Substances)